The final member of the EGFR family, ErbB4, is not well characterized in cancer and while existing clinical data for the potential role of ErbB4 in breast cancer are contradicting (Gullick, 2003) a number of activating mutations were recently identifed in non-small cell lung cancer (Kurppa et al., 2016). This evidence concerns the gene ERBB4 and cancer.